Abivax falls after Scorpion Capital discloses short position
ABVX•
ABVX•Abivax shares fell 8.3% to $73.98 after Scorpion Capital disclosed a short position in the French company. Scorpion said its 11-month investigation raised concerns about the safety disclosures for Abivax’s experimental drug obefazimod.
Scorpion Capital disclosed a short position in Abivax after an 11-month investigation. The firm alleged that obefazimod, Abivax’s experimental oral inflammatory bowel disease drug, could have photocarcinogenic potential, based on its lab experiments, and questioned the company’s skin-safety disclosures.
Scorpion said interviews with former employees involved in late-stage safety oversight raised questions about possible under-reporting and inadequate safety surveillance. It also alleged that Abivax’s scientific foundation and key claims relied on contaminated, retracted publications. Abivax did not immediately respond to a request for comment.